Eyelid

Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Research, CLD, Refractive surgery, ASCRS, Patient, Telecanthus, ARVO, University, Cataract, Abstract, Eyelid, Detail, Society, University of California, Irritation, Safety, MGD, Pain, Ophthalmic, Pharmaceutical industry

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).

Key Points: 
  • Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
  • This includes new, long-term data at ASCRS of the company’s lead drug candidate, AZR-MD-001, showing improvement in both signs and symptoms in MGD and Contact Lens Discomfort (CLD).
  • “Together, the data set we are presenting at these prestigious conferences show multiple potential patient benefits and mild, transient side effects in a topical medicine, supporting the potential of AZR-MD-001 as an entirely new approach targeting the underlying cause of many ocular surface diseases,” said Marc Gleeson, Chief Executive Officer of Azura.
  • This causes inflammatory ocular surface conditions, ocular surface dryness, pain, irritation, and reduced quality of vision.

Luxury Faux Lash Brand, Lilly Lashes, Launches Revolutionary Self-Adhesive Collection

Retrieved on: 
Monday, April 1, 2024
Beauty, Collection, Eye, Interview, Personality, Shahs of Sunset, ECO, Eyelid, 3D, Ulta, Sephora, Cosmetics

LOS ANGELES, April 1, 2024 /PRNewswire/ -- Lilly Lashes, founded by TV personality and entrepreneur Lilly Ghalichi, is excited to announce the launch of their one of a kind, new Self-Adhesive Collection SPR $16. The first on the prestige lash market, these revolutionary, innovative 3D Faux Mink lashes require no glue and are activated by your own body heat, have a 12-hour wear, are reusable for up to 5 wears, and leave no residue behind. The comfortable, pillowy, and tacky black band is made with ECO friendly ingredients, no harsh chemicals, and is safe for sensitive eyelids.

Key Points: 
  • LOS ANGELES, April 1, 2024 /PRNewswire/ -- Lilly Lashes, founded by TV personality and entrepreneur Lilly Ghalichi, is excited to announce the launch of their one of a kind, new Self-Adhesive Collection SPR $16 .
  • The comfortable, pillowy, and tacky black band is made with ECO friendly ingredients, no harsh chemicals, and is safe for sensitive eyelids.
  • Lilly Lashes has revolutionized the world of false lashes by creating the ultimate 3D lash concept with a promise to deliver on style, quality, and innovation.
  • Lilly Lashes is available to shop direct-to-consumer at www.lillylashes.com with exclusive styles available at Sephora and Ulta.

Prevent Blindness Provides Free Resources as Part of April's Women's Eye Health and Safety Month to Educate Women on Necessary Steps to Help Save Sight

Retrieved on: 
Wednesday, March 27, 2024
Orbis, IOP, Pigment, Glaucoma, Le Bonheur Children's Hospital, Social media, Pressure, Visual impairment, Contact, Paratriathlon, Intraocular pressure, AAO, Policy, Orbis International, Hormone, Diabetes, Risk, Mental health, Delta Gamma, NIH, Eyelid, Prevalence, Eye, Associate, Safety, Cataract, Menopause, University, Pregnancy, Hospital, Melasma, Public health, Lactation, Puberty, American Academy, Lens, Telecanthus, Eye disease, Graves' ophthalmopathy, Bangladesh Technical Education Board, Dry eye syndrome, Pediatrics, Birth control

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month. According to Orbis International, globally there are 112 million more women than men living with vision loss, including blindness. Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.

Key Points: 
  • CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month.
  • Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.
  • Women have a higher prevalence of age-related macular degeneration, cataract, dry eye, glaucoma, refractive error and thyroid eye disease.
  • For more information on women's eye health topics, including fact sheets on eye diseases and eye safety, please visit PreventBlindness.org.

triLift By Lumenis Receives Medical Device License from Health Canada, Launches in Canada

Retrieved on: 
Monday, March 25, 2024
Facial muscles, Facial, DOI, Face, Eye, Patient, SAN, Gold, Aesthetics, RF, MDL, IPL, Health Canada, Eyelid, CO2, Intense, Skin, Invention, Vision, Laser, Region, Cosmetic, Physician, Muscle atrophy, Ageing, Medical imaging

SAN JOSE, Calif., March 25, 2024 /PRNewswire/ -- Lumenis Be, Ltd., a global leader in developing and commercializing energy-based solutions for the Aesthetic and Vision markets, is proud to announce that the Facial Muscle Stimulation treatment that has taken over the U.S. is now coming to Canada. triLift, the groundbreaking Dynamic Muscle Stimulation technology (DMSt™), has received a Medical Device License (MDL) from Health Canada.

Key Points: 
  • triLift, the groundbreaking Dynamic Muscle Stimulation technology (DMSt™), has received a Medical Device License (MDL) from Health Canada.
  • Finally, practitioners in Canada can go beyond the skin, to address a key cause of facial aging—the muscles.
  • triLift by Lumenis is a unique device, allowing providers to target a patient's specific need with a quick, comfortable treatment option.
  • "The clearance of triLift by Health Canada is a significant moment in the Canadian facial aesthetics market," said Lumenis Vice President & Regional President, Americas, Brad Oliver.

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Retrieved on: 
Tuesday, March 5, 2024
Education, Inflammation, FDA, Irritation, MITES, Blepharitis, OD, Patient, Disease, Eyelid, Diagnosis, Science, Infestation, Human, TARS, Pharmaceutical industry

“Mite Party” is designed to elevate consumer awareness of Demodex blepharitis through relatable messaging and compelling visuals to encourage patients who may have Demodex blepharitis to seek out an eye care provider for screening.

Key Points: 
  • “Mite Party” is designed to elevate consumer awareness of Demodex blepharitis through relatable messaging and compelling visuals to encourage patients who may have Demodex blepharitis to seek out an eye care provider for screening.
  • “We are committed to increasing Demodex blepharitis education and awareness so that patients more effectively understand their disease and are motivated to seek treatment,” said Aziz Mottiwala, Chief Commercial Officer of Tarsus.
  • We look forward to advancing this novel campaign with the goal of helping as many patients with Demodex blepharitis as possible.”
    Demodex blepharitis occurs when Demodex mites – the most common ectoparasites found on humans – overpopulate on the eyelids.
  • “Mite Party” will officially launch on the XDEMVY Facebook page (@xdemvyrx) with a live event designed to “break up the mite parties” on Demodex blepharitis patients’ eyelids.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

Retrieved on: 
Wednesday, February 21, 2024
Allergy, ABBV, Senior, Woman, Injection, Research, ALS, Paratriathlon, Headache, Neck pain, Workplace, Education, Catherine Disher, Dream, Vitamin, Small business, Dizziness, Mentorship, Asthma, AbbVie, Weakness, Risk, AB toxin, Pain, Face, Human, COMMUNITY, BIPOC, Postal, Eyebrow, Confidence, Rash, Skin infection, Breast milk, Burnout, Myasthenia gravis, Eyelid, Lambert–Eaton myasthenic syndrome, Medication, Wheeze, Fatigue, Xerostomia, Partnership, Pharmaceutical industry

IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs. BOTOX® Cosmetic partnered with IFundWomen to launch the program in 2023, and in the second year, will award a new group of 20 women entrepreneurs each with $25,000 grants to fund and grow their businesses. Additionally, BOTOX® Cosmetic continues to support these businesses through mentorship, coaching, crowdfunding, and community.

Key Points: 
  • FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY
    IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs.
  • We are grateful to learn from them and thrilled to continue this program into a second year with a new cohort of extraordinary women entrepreneurs."
  • I am forever grateful to this program for connecting me to a group of women entrepreneurs who together are helping to bridge the Confidence Gap.
  • Starting today, women entrepreneurs across the country can apply for the BOTOX® Cosmetic x IFundWomen grant at www.botoxcosmetic.com/realimpact for the chance to be one of 20 recipients.

Acid attacks are a form of violence against women – the law needs to treat them as such

Retrieved on: 
Thursday, February 15, 2024
Social isolation, Permanent Damage, Hearing, Nitric acid, Violence, Woman, Scar, Poverty, Shame, Human, Education, Coercion, Sale, Crime, Survivor, Death, Family, Eyelid, Crown Prosecution Service, Motivation, Abuse, Police, Male, Research, Beauty, Drug

Sadly, acid attacks like this are not isolated incidents.

Key Points: 
  • Sadly, acid attacks like this are not isolated incidents.
  • Over the last 15 years, they have been on the rise across the world, including in the UK.
  • Those who target a victim’s face in particular aim to maim and disfigure, but not necessarily kill, their target.

Acid attacks as gendered violence

  • But what is often left out of the discussion is that it is a form of gendered violence that mainly targets women.
  • While acid attacks are perpetrated against both men and women, the vast majority of victims – 80% globally – are women, and the majority of perpetrators are male.
  • As a specialist in criminal justice responses to violence against women and girls, I have provided expert evidence in UK courts on the cultural contexts at play in cases of gender-based violence, including acid attacks.
  • Acid attacks remain common in India and the rest of South Asia, despite bans on the sale of acid over the counter.

How the law ignores violence against women

  • Although few acid attacks result in death, the intention to disfigure the victim permanently can still lead to a murder charge.
  • A number of UK women have reported not being taken seriously by police when they report threats of acid attacks.
  • Acid violence against women usually does not happen out of the blue.
  • This starts by acknowledging that these are not just horrific, random attacks – they are very often targeted violence against women.


Aisha K. Gill is affiliated with the End Violence Against Women Coalition

Screen time can seriously harm your eyes: here’s how to avoid it

Retrieved on: 
Tuesday, February 6, 2024
Tears, Telecanthus, Compostela, Panic, Thumb, Irritation, Patient, Prevalence, Itch, Temperature, COVID, Sand, Oil, Blinking, Sensation, Computer, Water, Protein, Quality of life, Tissue, Tablet, University, Screen time, Conjunctiva, Health, Eye, Eyelid, Lighting, Dry, Cosmetics

The most common symptoms include irritated or itchy eyes, and a sensation of dryness or sand on the surface of the eye.

Key Points: 
  • The most common symptoms include irritated or itchy eyes, and a sensation of dryness or sand on the surface of the eye.
  • Screens are also a source of projected light, which raises the temperature of the eye’s surface and increases tear evaporation.
  • According to the data we gathered, increased screen time was linked to more severe dry eye symptoms.


Although reducing screen time is impossible in certain jobs, we can reduce irritation and problems by following certain recommendations. A basic understanding of the issue can also help us to look after our eyes.

Teardrops and eyelids

  • The eye’s surface is made up of eyelids, the tear film (the eye’s liquid coating), the cornea and the conjunctiva.
  • If any of them are affected, it can lead to irritation in the eye.
  • The eyelids are what keep the tear film evenly distributed, as well as providing protection.

Do you suffer from dry eye disease?

  • First and foremost, there is often no cause for panic: suffering certain symptoms of dry eyes does not necessarily mean you have dry eye disease.
  • A medical professional will determine whether this damage exists, and what further measures need to be taken.

How to reduce irritation and avoid dry eye disease


By taking precautions, we can ensure that screens work with us, not against us.
Screen height: It is always best to keep screens below eye level. This way the eyelids do not have to open as much, meaning less of the eye’s surface is exposed for prolonged periods.
Screen position and lighting: You should avoid light reflecting off screens, be it from a lamp or from a window behind where you sit. Excessive light forces us to concentrate harder, and therefore to blink less. This can be solved by using anti reflective filters.
Rest periods: Rest is your eyes’ best friend. A common rule of thumb is the 20-20-20 rule. For every 20 minutes of work, look at something 20 feet away (about 6 metres), for 20 seconds. This has been proven to reduce symptoms of eye dryness, as looking away from the screen re establishes our normal rate of blinking.
Environmental conditions: Low humidity, high temperatures, air currents from open windows or air conditioners, tobacco smoke and excessive air freshener can all be bad for eye health.
Eye hydration: Eye drops may be the best option on particularly intense working days. Avoid saline solutions, as their composition is not the same as the tear film. They lack the oils and proteins, and could destabilise this layer. The best option is single dose artificial tears, which do not contain preservatives and do not damage the eye.
The prevalence of screens in our society means that symptoms of dry eye disease are commonplace. If we confront this issue by taking the right steps, however, it doesn’t have to affect our quality of life.
Las personas firmantes no son asalariadas, ni consultoras, ni poseen acciones, ni reciben financiación de ninguna compañía u organización que pueda obtener beneficio de este artículo, y han declarado carecer de vínculos relevantes más allá del cargo académico citado anteriormente.

Scientists operated a Cybertruck from dreams (VIDEO)

Retrieved on: 
Monday, February 5, 2024
ResearchGate, Human, Light, Dream, Music, Canadian International Council, PsyArXiv, Polysomnography, Speech, Computer, Inception, Preprint, REM, Eyelid, Movement

REDWOOD CITY, Calif., Feb. 5, 2024 /PRNewswire/ -- Researchers from California startup REMspace have achieved the first two-way control of a virtual object from a lucid dream. The results of the experiment were approved for publication in the scientific journal International Journal of Dream Research.  

Key Points: 
  • The results of the experiment were approved for publication in the scientific journal International Journal of Dream Research.
  • We spend a third of our lives asleep, and humanity dreams of using this time profitably, just as the heroes of the movie Inception did.
  • If a person moved their legs in a dream, this led to the movement of a virtual avatar (Cybertruck) on the computer screen.
  • According to Michael Raduga, leader of the experiment, "Two-way interaction with a computer from dreams opens up a whole area of new technologies.

CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China

Retrieved on: 
Monday, January 22, 2024
Senior, Lupus, Paresthesia, Heat, Diabetes, Face, FLX, Blister, Growth, CPT, Epilepsy, Bausch Health, Genital herpes, Breastfeeding, Burns, Hypoesthesia, Glycine mollis, Eyelid, National Medical Products Administration, BHC, NMPA, Medical device

[See *Correction above: The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration.]

Key Points: 
  • [See *Correction above: The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration.]
  • "The approval of Thermage FLX, and the TR-4 return pad, marks a significant milestone for Solta Medical," Thomas J. Appio, Bausch Health Chief Executive Officer, said.
  • "The approval from NMPA means we are able to continue the momentum of the growth of Thermage in China," Jiny Kim, Senior Vice President, Solta Medical, said.
  • Ask your doctor for more information about Thermage FLX and see www.thermage.com for additional details.